PrimeCell Overview

  • Founded
  • 2007

Founded
  • Status
  • Private

  • Employees
  • 100

Employees
  • Latest Deal Type
  • 2ndary - Private

  • Financing Rounds
  • 2

  • Investments
  • 1

PrimeCell General Information

Description

Developer of regenerative medicine focused on discovering and clinical testing of biological drugs and medicinal technologies. The company's scientific and manufacturing infrastructure utilizes technologies to develop, process and manufacture human cell and tissue products that change genes and cells parameters to support the regeneration of human tissues and organs, thereby enabling physicians and patients with new treatments that use human cells and new materials such as nanomaterials to treat serious diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • BioIncubator 4MEDi, University Hospital
  • Dr. Slabihoudka 11
  • Ostrava, 708 00
  • Czech Republic

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PrimeCell Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PrimeCell‘s full profile, request access.

Request a free trial

PrimeCell Patents

PrimeCell Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3851853-A1 Method for separation of sperm with undamaged intact heads from sperm with damaged heads and somatic cells Inactive 17-Jan-2020 00000000000 0
EP-4090972-A1 Method for separation of sperm with undamaged intact heads from sperm with damaged heads and somatic cells Pending 17-Jan-2020 00000000000
US-20230044560-A1 Method for separation of sperm with undamaged intact heads from sperm with damaged heads and somatic cells Pending 17-Jan-2020 000000000
EP-3851852-A1 Method for separation of sperm with undamaged intact heads from sperm with damaged heads and somatic cells Inactive 17-Jan-2020 0000000000 0
EP-4090971-A1 Method for separation of sperm with undamaged intact heads from sperm with damaged heads and somatic cells Pending 17-Jan-2020 G01N33/689
To view PrimeCell’s complete patent history, request access »

PrimeCell Executive Team (8)

Name Title Board Seat Contact Info
Serhiy Forostyak Ph.D Chief Scientific Officer
Petr Koška Ph.D Chief Executive Officer & Vice Chairman, National Cell and Tissue Centre
You’re viewing 2 of 8 executive team members. Get the full list »

PrimeCell Board Members (3)

Name Representing Role Since
000 0000000 PrimeCell Member of the Board of Trustees 000 0000
0000 00š00 00.0 Self Chief Executive Officer & Vice Chairman, National Cell and Tissue Centre 000 0000
You’re viewing 2 of 3 board members. Get the full list »

PrimeCell Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PrimeCell Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000á 00000 21-Dec-2020 0000000000 00.00 Other Healthcare Services
To view PrimeCell’s complete investments history, request access »

PrimeCell Subsidiaries (1)

Company Name Industry Location Founded
000000á 00000 0000 Other Healthcare Services Ostrava, Czech Republic 0000
To view PrimeCell’s complete subsidiaries history, request access »